<?xml version='1.0' encoding='utf-8'?>
<document id="31726287"><sentence text="Initial assessment of an interprofessional team-delivered telehealth program for patients with epilepsy." /><sentence text="Epilepsy affects 3" /><sentence text="5 million people in the United States (US)" /><sentence text=" Rural-dwelling individuals have less access to healthcare and consequently poorer health outcomes" /><sentence text=" This study describes the outcomes of an interprofessional telehealth program for rural-dwelling individuals with epilepsy in one US state" /><sentence text="" /><sentence text="An academic medication therapy management pharmacist provided clinical services to rural-dwelling individuals with epilepsy between November 2015 and June 2018, using video-conferencing technology and follow-up telephonic consultation" /><sentence text=" Data collected included: demographics, prescribed seizure medications, comorbidities, drug-drug and drug-disease interactions, adverse drug reactions, therapeutic duplications, dose-related safety concerns, adherence concerns, and recommendations to resolve identified issues" /><sentence text=" Data were summarized using appropriate descriptive statistics" /><sentence text="" /><sentence text="A total of 168 patients (51% male, mean age 28 ± 15 years), participated in this pilot study" /><sentence text=" Most participants (94%) were prescribed at least one seizure medication including: benzodiazepines (n = 89), lamotrigine (n = 58), and levetiracetam (n = 56)"><entity charOffset="84-99" id="DDI-PubMed.31726287.s12.e0" text="benzodiazepines" /><entity charOffset="110-121" id="DDI-PubMed.31726287.s12.e1" text="lamotrigine" /><entity charOffset="136-149" id="DDI-PubMed.31726287.s12.e2" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.31726287.s12.e0" e2="DDI-PubMed.31726287.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31726287.s12.e0" e2="DDI-PubMed.31726287.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31726287.s12.e0" e2="DDI-PubMed.31726287.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31726287.s12.e1" e2="DDI-PubMed.31726287.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31726287.s12.e1" e2="DDI-PubMed.31726287.s12.e2" /></sentence><sentence text=" The majority (55%) had at least one comorbidity including: mood disorders (n = 49) and psychiatric disorders (n = 26)" /><sentence text=" Common medications with reported precautions for people with a seizure history were: selective serotonin reuptake inhibitors (n = 18), second-generation atypical antipsychotics (n = 17) and benzodiazepines (n = 16)"><entity charOffset="96-105" id="DDI-PubMed.31726287.s14.e0" text="serotonin" /><entity charOffset="191-206" id="DDI-PubMed.31726287.s14.e1" text="benzodiazepines" /><pair ddi="false" e1="DDI-PubMed.31726287.s14.e0" e2="DDI-PubMed.31726287.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31726287.s14.e0" e2="DDI-PubMed.31726287.s14.e1" /></sentence><sentence text=" Participants had at least one: drug-disease interaction (33%), drug-drug interaction (54%), adverse drug reaction (37%), therapeutic duplication (13%); dose-related safety concerns (35%); and medication utilization concerns (13%)" /><sentence text="" /><sentence text="This pharmacist-delivered pilot program was effective in: reaching underserved patients with epilepsy, identifying and recommending resolutions to medication-related problems, and demonstrating the value of pharmacists in an interprofessional team" /><sentence text=" Further work is warranted to identify telehealth strategies to reduce medication associated problems" /><sentence text="" /></document>